Finally, T2DM management should be individualized to minimize hypoglycemia and falls and to avoid agents that may have negative skeletal effects (eg, insulin therapy, sulfonylureas, thiazolidinediones, and canagliflozin). This evidence concerns the gene INS and Hypoglycemia.